Molecular Therapy - Nucleic Acids

Slides:



Advertisements
Similar presentations
Figure 1. Gene expression analysis
Advertisements

Molecular Therapy - Nucleic Acids
Repression of COUP-TFI Improves Bone Marrow-Derived Mesenchymal Stem Cell Differentiation into Insulin-Producing Cells  Tao Zhang, Xiao-Hang Li, Dian-Bao.
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
An RNA Molecule Derived From Sendai Virus DI Particles Induces Antitumor Immunity and Cancer Cell-selective Apoptosis  Li-Wen Liu, Tomoyuki Nishikawa,
Factor VII-Induced MicroRNA-135a Inhibits Autophagy and Is Associated with Poor Prognosis in Hepatocellular Carcinoma  Kuang-Tzu Huang, I-Ying Kuo, Ming-Chao.
Figure 1. Effect of acute TNF treatment on transcription in human SGBS adipocytes as assessed by RNA-seq and RNAPII ChIP-seq. Following 10 days in vitro.
A Novel Cofactor for p300 that Regulates the p53 Response
Volume 53, Issue 6, Pages (March 2014)
Volume 16, Issue 1, Pages (January 2008)
Global Mapping of Human RNA-RNA Interactions
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Antisense Oligonucleotides Targeting Y-Box Binding Protein-1 Inhibit Tumor Angiogenesis by Downregulating Bcl-xL-VEGFR2/-Tie Axes  Kiyoko Setoguchi, Lin.
Volume 54, Issue 1, Pages (April 2014)
Volume 24, Issue 11, Pages (June 2014)
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Gapmer Antisense Oligonucleotides Suppress the Mutant Allele of COL6A3 and Restore Functional Protein in Ullrich Muscular Dystrophy  Elena Marrosu, Pierpaolo.
Human Senataxin Resolves RNA/DNA Hybrids Formed at Transcriptional Pause Sites to Promote Xrn2-Dependent Termination  Konstantina Skourti-Stathaki, Nicholas J.
Volume 25, Issue 6, Pages (June 2017)
Uc.454 Inhibited Growth by Targeting Heat Shock Protein Family A Member 12B in Non- Small-Cell Lung Cancer  Jun Zhou, Chenghai Wang, Weijuan Gong, Yandan.
Volume 25, Issue 9, Pages (September 2017)
Volume 25, Issue 3, Pages (March 2017)
Volume 19, Issue 10, Pages (June 2017)
Inhibition of KLF4 by Statins Reverses Adriamycin-Induced Metastasis and Cancer Stemness in Osteosarcoma Cells  Yangling Li, Miao Xian, Bo Yang, Meidan.
Molecular Therapy - Nucleic Acids
Volume 22, Issue 3, Pages (March 2015)
Molecular Therapy - Nucleic Acids
The Efficacy of siRNAs against Hepatitis C Virus Is Strongly Influenced by Structure and Target Site Accessibility  Selena M. Sagan, Neda Nasheri, Christian.
MiR-125b, a MicroRNA Downregulated in Psoriasis, Modulates Keratinocyte Proliferation by Targeting FGFR2  Ning Xu, Petter Brodin, Tianling Wei, Florian.
Ribosomal Protein S3 Gene Silencing Protects Against Cigarette Smoke-Induced Acute Lung Injury  Jinrui Dong, Wupeng Liao, Hong Yong Peh, W.S. Daniel Tan,
Control of HCV Replication With iMIRs, a Novel Anti-RNAi Agent
A Rapamycin-Activated Caspase 9-Based Suicide Gene
Codon-Optimized P1A-Encoding DNA Vaccine: Toward a Therapeutic Vaccination against P815 Mastocytoma  Alessandra Lopes, Kevin Vanvarenberg, Véronique Préat,
Molecular Therapy - Nucleic Acids
Induced-Decay of Glycine Decarboxylase Transcripts as an Anticancer Therapeutic Strategy for Non-Small-Cell Lung Carcinoma  Jing Lin, Jia Hui Jane Lee,
Induced-Decay of Glycine Decarboxylase Transcripts as an Anticancer Therapeutic Strategy for Non-Small-Cell Lung Carcinoma  Jing Lin, Jia Hui Jane Lee,
Alterations in mRNA 3′ UTR Isoform Abundance Accompany Gene Expression Changes in Human Huntington’s Disease Brains  Lindsay Romo, Ami Ashar-Patel, Edith.
Molecular Therapy - Nucleic Acids
Volume 21, Issue 9, Pages (November 2017)
Molecular Therapy - Nucleic Acids
Volume 9, Issue 3, Pages (March 2009)
Suppression of IGF1R in Melanoma Cells by an Adenovirus-Mediated One-Step Knockdown System  Haoran Xin, Mingxing Lei, Zhihui Zhang, Jie Li, Hao Zhang,
Volume 25, Issue 8, Pages (August 2017)
Volume 65, Issue 4, Pages e4 (February 2017)
Molecular Therapy - Nucleic Acids
Increased Expression of Laminin Subunit Alpha 1 Chain by dCas9-VP160
A CTLA-4 Antagonizing DNA Aptamer with Antitumor Effect
Long Noncoding RNA BC as a Novel Therapeutic Target for Colorectal Cancer that Suppresses Metastasis by Upregulating TIMP3  Jiaxin Lin, Xin Tan,
Amanda O'Donnell, Shen-Hsi Yang, Andrew D. Sharrocks  Molecular Cell 
Volume 25, Issue 5, Pages (May 2017)
Volume 15, Issue 12, Pages (June 2016)
Negative Regulation of Tumor Suppressor p53 by MicroRNA miR-504
Smith-Magenis Syndrome Results in Disruption of CLOCK Gene Transcription and Reveals an Integral Role for RAI1 in the Maintenance of Circadian Rhythmicity 
Volume 11, Issue 3, Pages (April 2015)
Volume 26, Issue 3, Pages (March 2018)
Triplex-forming Peptide Nucleic Acids Induce Heritable Elevations in Gamma-globin Expression in Hematopoietic Progenitor Cells  Joanna Y Chin, Faisal.
Molecular Therapy - Nucleic Acids
Volume 24, Issue 10, Pages (October 2016)
Michael U. Shiloh, Paolo Manzanillo, Jeffery S. Cox 
Gemcitabine-Incorporated G-Quadruplex Aptamer for Targeted Drug Delivery into Pancreas Cancer  Jun Young Park, Ye Lim Cho, Ju Ri Chae, Sung Hwan Moon,
Rumwald Leo G Lecaros, Leaf Huang, Tsai-Chia Lee, Yih-Chih Hsu 
Jörg Hartkamp, Brian Carpenter, Stefan G.E. Roberts  Molecular Cell 
SUPT4H1 Depletion Leads to a Global Reduction in RNA
Volume 27, Issue 5, Pages (May 2019)
Molecular Therapy - Nucleic Acids
Volume 27, Issue 9, Pages (September 2019)
Volume 24, Issue 11, Pages (June 2014)
Presentation transcript:

Molecular Therapy - Nucleic Acids A Sensitive In Vitro Approach to Assess the Hybridization-Dependent Toxic Potential of High Affinity Gapmer Oligonucleotides  Andreas Dieckmann, Peter H. Hagedorn, Yvonne Burki, Christine Brügmann, Marco Berrera, Martin Ebeling, Thomas Singer, Franz Schuler  Molecular Therapy - Nucleic Acids  Volume 10, Pages 45-54 (March 2018) DOI: 10.1016/j.omtn.2017.11.004 Copyright © 2017 F. Hoffmann-La Roche Ltd Terms and Conditions

Figure 1 Apoptosis Induction In Vitro Reveals the Hepatotoxic Potential of LNA-ASOs Mouse 3T3 fibroblast cells were transfected using Lipofectamine 2000 with well-tolerated and hepatotoxic LNA-ASOs, respectively. Caspase 3/7 activity was measured 24 hr later. Triplicate transfections were performed; the results are shown as a percentage change relative to UTCs. Data are mean ± SD. Molecular Therapy - Nucleic Acids 2018 10, 45-54DOI: (10.1016/j.omtn.2017.11.004) Copyright © 2017 F. Hoffmann-La Roche Ltd Terms and Conditions

Figure 2 In Vitro Caspase 3/7 Induction Is Stronger for Hepatotoxic Than for Well-Tolerated LNA-ASOs Mouse 3T3 fibroblast cells were transfected using Lipofectamine 2000 with 236 different LNA-ASOs at 100 nM. Caspase 3/7 activity was measured 24 hr later. Duplicate transfections were performed, and the values were calculated as average percentage change relative to UTCs. The LNA-ASOs were separated into two groups of lower and higher hepatotoxicity in vivo (i.e., mean ALT levels ≤5-fold or >5-fold, respectively, relative to saline-treated mice after intravenous (i.v.) treatment with 5 × 15 mg/kg LNA-ASOs6). Each group of LNA-ASOs is listed versus their respective caspase values determined in vitro in a boxplot diagram. For each group, the number (count) of included LNA-ASOs, the median caspase activities, and the number of outliers is shown. The level of significance as evaluated by Wilcoxon rank sum test is indicated above the boxplot. Molecular Therapy - Nucleic Acids 2018 10, 45-54DOI: (10.1016/j.omtn.2017.11.004) Copyright © 2017 F. Hoffmann-La Roche Ltd Terms and Conditions

Figure 3 RNase H1 Knockdown Suppresses LNA-ASO Toxicity In Vitro (A) Mouse 3T3 fibroblast cells were transfected with a siRNA against RNase H1 (light gray bars) and a control (ctr.) siRNA (dark gray bars) at 10 nM, respectively, using Lipofectamine 2000. 24 hr later, cells were transfected with the hepatotoxic LNA41 or LNA37 at 30 nM using Lipofectamine 2000. Caspase 3/7 activity was measured 24 hr later. (B) siRNA transfection was performed as in (A) and cells were harvested 48 hr later for assessing RNase H1 knockdown by qPCR. Results in (A) and (B) are shown as a percentage change relative to UTCs. Data (n = 3) are mean ± SD. Molecular Therapy - Nucleic Acids 2018 10, 45-54DOI: (10.1016/j.omtn.2017.11.004) Copyright © 2017 F. Hoffmann-La Roche Ltd Terms and Conditions

Figure 4 2′-OMe Modifications in the Gap Region of Hepatotoxic LNA-ASOs Suppress Toxicity In Vitro Left: schematic illustration of the parent LNA41 and LNA37 ASOs and their 2′-OMe-modified versions LNA41’ and LNA37’ (with two 2′-OMe-modifications in the gap region) and LNA41” and LNA37” (with ten 2′-OMe modifications in the gap region). Right: caspase activity measured 24 hr after transfection of mouse 3T3 fibroblast cells with the indicated LNA-ASOs at 30 nM. Results are shown as a percentage change relative to UTCs. Data (n = 3) are mean ± SD. Molecular Therapy - Nucleic Acids 2018 10, 45-54DOI: (10.1016/j.omtn.2017.11.004) Copyright © 2017 F. Hoffmann-La Roche Ltd Terms and Conditions

Figure 5 2′-OMe Modifications in the Gap Region of Hepatotoxic LNA-ASOs Suppress Downregulation of Their Intended Target Myd88 expression was determined 24 hr after transfection of mouse 3T3 fibroblast cells with the indicated LNA-ASOs at 30 nM. Results are shown as a percentage change relative to UTCs. Data (n = 3) are mean ± SD. Molecular Therapy - Nucleic Acids 2018 10, 45-54DOI: (10.1016/j.omtn.2017.11.004) Copyright © 2017 F. Hoffmann-La Roche Ltd Terms and Conditions

Figure 6 Effect of Hepatotoxic LNA41 and Its 2′-OMe-Gap-Modified Version LNA41’ on Gene Expression in Mouse Fibroblast Cells Mouse 3T3 fibroblast cells were transfected with LNA41 and 2′-OMe-modified LNA41’, respectively, at 30 nM in triplicates, and were then harvested at 3 and 6 hr, respectively. Gene array analysis was performed and only genes were considered, which were significantly (p value ≤ 0.01) de-regulated by at least 2-fold (indicated by the dashed red lines; number of respective genes identified are in blue) from the untreated control (dashed black lines) at the 6-hr time point for LNA41. (A) shows the downregulatory trends of the identified genes between 3 and 6 hr after transfection. The red dashed oval and the arrow indicate the downregulation trends for the LNA41 target transcript Myd88; the remaining Myd88 transcript levels are indicated as fold change relative to control. (B) shows the upregulatory trends of the identified genes between 3 and 6 hr after transfection Molecular Therapy - Nucleic Acids 2018 10, 45-54DOI: (10.1016/j.omtn.2017.11.004) Copyright © 2017 F. Hoffmann-La Roche Ltd Terms and Conditions

Figure 7 Higher Affinity LNA-ASOs Tend to Be More Toxic In Vitro and In Vivo (A) The 236 LNA-ASOs were separated into two groups with in vivo mean ALT levels ≤5-fold and >5-fold from saline-treated mice, respectively. For each group, the respective theoretical Tm values were calculated and summarized in a boxplot diagram. (B) The 236 LNA-ASOs were separated into four Tm ranges, as indicated. For each Tm range, the oligonucleotides’ respective caspase values were listed in a boxplot diagram. In addition, for each group in (A) and (B) the number (count) of included LNA-ASOs, the median Tm (for A) and caspase (for B) values, and the number of outliers are shown. The level of significance as evaluated by Wilcoxon rank sum test is indicated above the boxplots in (A). Molecular Therapy - Nucleic Acids 2018 10, 45-54DOI: (10.1016/j.omtn.2017.11.004) Copyright © 2017 F. Hoffmann-La Roche Ltd Terms and Conditions

Figure 8 Melting Temperature, Tm, Calculations Facilitate the Design of LNA-ASOs with Low Toxic Potential Mouse 3T3 fibroblast cells were transfected using Lipofectamine 2000 with ten low-binding affinity (Tm < 50°C; dark gray bars) and ten high-binding affinity (Tm > 60°C; black bars) LNA-ASOs targeting mouse Gapdh, respectively, at 30 nM. Caspase 3/7 activity was measured 24 hr later. Results are shown as a percentage change relative to UTCs. Data (n = 3) are mean ± SD. Molecular Therapy - Nucleic Acids 2018 10, 45-54DOI: (10.1016/j.omtn.2017.11.004) Copyright © 2017 F. Hoffmann-La Roche Ltd Terms and Conditions

Figure 9 Effect of the Wing Design on Binding Affinity and LNA-SSO Toxicity Left: schematic illustration of the parent mGAPDH_LNA1189 and its DNA-substituted wing variants with their respective calculated Tms. Right: caspase activity measured 24 hr after transfection of mouse 3T3 fibroblast cells with the indicated LNA-ASOs at 30 nM. Results are shown as a percentage change relative to UTCs. Data (n = 3) are mean ± SD. Molecular Therapy - Nucleic Acids 2018 10, 45-54DOI: (10.1016/j.omtn.2017.11.004) Copyright © 2017 F. Hoffmann-La Roche Ltd Terms and Conditions

Figure 10 Selected Hepatotoxic LNA-ASOs Also Exert Their Toxic Potential in Different Human Tumor Cells A549, HeLa, and HepG2 cells were transfected using Lipofectamine 2000 with the well-tolerated LNA32 and LNA33 (light gray bars) and the hepatotoxic LNA41 and LNA43 (dark gray bars), respectively, at 30 nM. Caspase 3/7 activity was measured 24 hr later. Triplicate transfections were performed, and the results are shown as a percentage change relative to UTCs. Data are mean ± SD. Molecular Therapy - Nucleic Acids 2018 10, 45-54DOI: (10.1016/j.omtn.2017.11.004) Copyright © 2017 F. Hoffmann-La Roche Ltd Terms and Conditions